Hair Diseases: Clinical Trials

353 completed, 129 unknown, 83 recruiting, 46 not yet recruiting. 256 Not applicable, 180 Phase 2, 86 Phase 3, 84 Phase 1, 52 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	256	Completed 120, Unknown 54, Recruiting 27, Active not recruiting 14, Not yet recruiting 13, Withdrawn 13, Terminated 12, Enrolling by invitation 3
Phase 2	180	Completed 93, Recruiting 21, Unknown 21, Terminated 13, Not yet recruiting 12, Withdrawn 10, Active not recruiting 8, Enrolling by invitation 1, Suspended 1
Phase 3	86	Completed 45, Recruiting 13, Not yet recruiting 9, Active not recruiting 7, Unknown 7, Terminated 3, Suspended 1, Withdrawn 1
Phase 1	84	Completed 38, Unknown 20, Recruiting 13, Terminated 5, Not yet recruiting 3, Active not recruiting 2, Withdrawn 2, Enrolling by invitation 1
Phase 4	52	Completed 26, Unknown 12, Not yet recruiting 6, Recruiting 3, Terminated 3, Withdrawn 2
Early Phase 1	21	Completed 10, Unknown 4, Not yet recruiting 2, Terminated 2, Active not recruiting 1, Recruiting 1, Withdrawn 1

Follow Hair Diseases: new trials by email Literature Review of Hair Diseases trials Research Report on Hair Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. Minoxidil oral solution, Placebo oral solution - Androgenetic Alopecia, Androgenetic Alopecia (AGA)	Phase 3	Not yet recruiting	Eurofarma Laboratorios S.A.	372	2027-01-31	2026-04-14
A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopecia Minoxidil 5 %, Microneedling - Androgenetic Alopecia	Not applicable	Not yet recruiting	Cheng Zhou	190	2027-01-01	2026-08-11
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN) N1087, Placebo - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia	Phase 3	Not yet recruiting	Eurofarma Laboratorios S.A.	372	2027-01-01	2026-01-09
Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial Platelet-Rich Plasma (PRP) Injections, Red-light photobiomodulation with cooling, Blue-light photobiomodulation - Androgenetic Alopecia	Early Phase 1	Not yet recruiting	Kimberly Meathrel	30	2026-12-30	2026-07-31
XVIE to Treat Androgenetic Alopecia (AGA) Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution - Androgenetic Alopecia	Phase 1 / Phase 2	Not yet recruiting	Restore Biologics Holdings, Inc. dba Xtressé	30	2026-12-01	2026-08-12
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia	Phase 2 / Phase 3	Not yet recruiting	Sherief Ayman Hussein Shaamash	40	2026-12-01	2026-10-07
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia APSMNF 1, APSMNF 2, Eniagor® - Alopecia, Androgenetic	Phase 3	Not yet recruiting	Apsen Farmaceutica S.A.	336	2026-10-07	2026-09-08
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use Dietary Supplement for Hair Loss - Alopecia	Not applicable	Not yet recruiting	Farmoquimica S.A.	48	2026-10-01	2026-08-27
Oral Minoxidil With or Without a Multifactorial Drinkable Nutraceutical in Female Pattern Hair Loss: a Retrospective Study Oral low-dose Minoxidil, Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women. - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia		Not yet recruiting	Olistic Research Labs S.L.	30	2026-10-01	2026-10-07
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side - Androgenic Alopecia	Early Phase 1	Not yet recruiting	Wake Forest University Health Sciences	16	2026-10-01	2026-08-04
Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women. - Gut Dysbiosis, Telogen Effluvium		Not yet recruiting	Olistic Research Labs S.L.	30	2026-10-01	2026-10-09
Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata Calcipotriol, Triamcinolone Acetonide - Alopecia Areata	Phase 4	Not yet recruiting	Hayat Abad Medical Complex, Peshawar	60	2026-10-01	2026-09-21
The Role of Gut and Skin Microbiota in Alopecia Areata Fecal Microbial Transplant Enema, Placebo - Alopecia Areata, Fecal Microbiota Transplantation (FMT)	Not applicable	Not yet recruiting	Polyclinic GrandMed	30	2026-10-01	2026-07-15
Evidence-Based Integrated Protocol to Maximize Hair Follicle Survival in Follicular Unit Extraction (FUE) Integrated Evidence-Based FUE Protocol, Standard FUE Practice - Androgenetic Alopecia, Cicatricial Alopecia	Not applicable	Not yet recruiting	Assiut University	30	2026-10-01	2026-09-30
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast, formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast, Placebo (maltodextrin) - Androgenic Alopecia, Healthy Adult Male	Not applicable	Not yet recruiting	Activ'inside	99	2026-09-30	2026-09-08
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia Xtressé Hair Growth Gummies, Placebo Comparator - Androgenic Alopecia, Hair Loss/Baldness	Not applicable	Not yet recruiting	Restore Biologics Holdings, Inc. dba Xtressé	48	2026-09-29	2026-08-17
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata VC005 tablets - Alopecia Areata	Phase 1	Recruiting	Jiangsu vcare pharmaceutical technology co., LTD	24	2026-09-22	2026-10-20
Phase 2/3 Efficacy and Safety of PP405 in Adult Males PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia	Phase 2 / Phase 3	Recruiting	Pelage Pharmaceuticals, Inc.	600	2026-09-21	2026-10-22
Tirzepatide for Treatment of CCCA Tirzepatide - Central Centrifugal Cicatricial Alopecia (CCCA)	Phase 2	Recruiting	Johns Hopkins University	20	2026-09-15	2026-09-23
Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA) Delgocitinib - Frontal Fibrosing Alopecia	Phase 2	Not yet recruiting	Maryanne Makredes Senna	30	2026-09-10	2026-08-26

Showing 20 of 732. Sign in to see all of them.

Narrower conditions

Alopecia (469)  ·  Alopecia Areata (219)  ·  Hirsutism (40)  ·  Alopecia universalis (29)  ·  Dermatitis, Atopic (20)  ·  Psoriasis (19)  ·  Vitiligo (18)  ·  Breast Neoplasms (17)  ·  Polycystic Ovary Syndrome (17)  ·  Acne Vulgaris (15)  ·  Hidradenitis Suppurativa (13)  ·  Hypotrichosis (13)  ·  Hypertrichosis (11)  ·  Skin Diseases (11)

Broader conditions

Skin and Connective Tissue Diseases (732)  ·  Skin Diseases (721)  ·  Hypotrichosis (648)  ·  Pathological Conditions, Signs and Symptoms (522)  ·  Pathological Conditions, Anatomical (471)  ·  Alopecia (183)  ·  Neoplasms (56)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (48)  ·  Signs and Symptoms (48)  ·  Virilism (40)  ·  Genetic Diseases, Inborn (38)  ·  Immune System Diseases (38)  ·  Pathologic Processes (33)  ·  Endocrine System Diseases (31)

Interventions

Minoxidil (54)  ·  Solutions (20)  ·  Triamcinolone Acetonide (17)  ·  Bimatoprost (14)  ·  Finasteride (13)  ·  Sodium Chloride (11)  ·  baricitinib (10)  ·  tofacitinib (9)  ·  Methotrexate (8)  ·  Saline Solution (8)  ·  Dutasteride (7)  ·  Dietary Supplements (5)  ·  Injections (5)  ·  Lasers, Solid-State (5)  ·  Latanoprost (5)

Sponsors

Pfizer (17)  ·  Assiut University (16)  ·  Allergan (12)  ·  University of Minnesota (12)  ·  Aderans Research Institute (11)  ·  Applied Biology, Inc. (9)  ·  Cairo University (9)  ·  Sohag University (9)  ·  Suzhou Kintor Pharmaceutical Inc, (9)  ·  Icahn School of Medicine at Mount Sinai (8)  ·  Kasr El Aini Hospital (8)  ·  Columbia University (7)  ·  Ablon Skin Institute Research Center (6)  ·  Concert Pharmaceuticals (6)  ·  Erasmus Medical Center (6)

Countries

United States (312)  ·  China (55)  ·  Egypt (52)  ·  Canada (38)  ·  Spain (36)  ·  France (33)  ·  Germany (32)  ·  South Korea (30)  ·  Australia (26)  ·  United Kingdom (23)  ·  Taiwan (22)  ·  Japan (21)  ·  Italy (18)  ·  Poland (18)  ·  India (17)

Top investigators

Maria Hordinsky, MD (10)  ·  Julian Mackay-Wiggan, MD, MS (6)  ·  Andy Goren, MD (4)  ·  Glynis Ablon, MD, FAAD (4)  ·  Kseniya Kobets, MD (4)  ·  Maria K Hordinsky, MD (4)  ·  Reid Waldman, M.D. (4)  ·  Timothy Durso, M.D. (4)  ·  Abe Marcadis, M.D. (3)  ·  Brett King, MD, PhD (3)  ·  Emma Guttman, MD, PhD (3)

Results publications

PMID 38263353, PMID 41917311, PMID 42481842, PMID 25013998, PMID 25896390, PMID 26507877, PMID 27699252, PMID 28300084, PMID 28619556, PMID 29273099, PMID 35334197, PMID 36763878, PMID 36855020, PMID 37381691, PMID 37556146, PMID 37917289, PMID 37991697, PMID 38904749, PMID 39962358, PMID 40214720, PMID 42823604, PMID 42825995, PMID 10327298, PMID 10495374, PMID 10583059, PMID 10677100, PMID 11511857, PMID 1188424, PMID 12789165, PMID 14582678, PMID 15034503, PMID 15577756, PMID 15923132, PMID 16278898, PMID 16417220, PMID 16616302, PMID 17196507, PMID 17236136, PMID 1739290, PMID 17482283, PMID 17536071, PMID 17557889, PMID 17569567, PMID 17637820, PMID 17761356, PMID 17785709, PMID 18256395, PMID 18329131, PMID 18375410, PMID 18489053

NIH funding

2025 (4), 2017 (3), 2023 (3), 2016 (2), 2004 (1), 2009 (1), 2018 (1), P30CA013330 (1), R03CA088598 (1), R33AR077495 (1), R61AR084210 (1)